LAMA novel formulation
Circassia’s product is a novel particle-engineered formulation of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide. The product is in development as an inhaled monotherapy for chronic obstructive pulmonary disease (COPD).
Our product is a drug-only glycopyrronium bromide formulation delivered via pressurized metered dose inhaler (pMDI). The product doesn’t require cold chain supply, and can be delivered by simple multi-dose pMDI devices, in contrast to current dry powder formulations that require a new single-dose capsule for each use.
It has successfully completed a phase IIa clinical study in patients with moderate-to-severe COPD. The randomized, double-blind, single-dose study met its primary endpoint demonstrating that all doses significantly improved lung function compared to placebo. The product also demonstrated good tolerability and safety. It is currently partnered in China, Taiwan, Hong Kong and Macau, and because it does not fit Circassia’s strategy of focusing on specialist and substitutable medicines the company plans to partner the product in other markets for further development and commercialization.
Pipeline status: LAMA novel formulation
Registration Study /